<DOC>
	<DOCNO>NCT02665650</DOCNO>
	<brief_summary>The purpose study establish dose regimen combination therapy AFM13 pembrolizumab ( MK-3475 ) patient relapse refractory ( R/R ) Hodgkin Lymphoma ( HL ) ass safety tolerability combination therapy .</brief_summary>
	<brief_title>Study Combination AFM13 Pembrolizumab Patients With Relapsed Refractory Classical Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Main 1 . Diagnosis CD30+ classical Hodgkin lymphoma reconfirm histopathology . Note : reconfirmation possible , patient still eligible confirmation clearly document medical record . 2 . Relapsed refractory disease standard therapy include brentuximab vedotin ( AdcetrisÂ® ) . 3 . Completion , applicable , radiotherapy , chemotherapy , antibody immunoconjugates include brentuximab vedotin and/or another investigational drug could interact trial less 4 week ( 5 halflives drug , whichever occurs later ) prior first dose study drug . Cessation small molecule tyrosine kinase inhibitor must least 7 day prior first dose study drug . 4 . Completion , applicable , autologous stem cell transplantation ( ASCT ) least 3 month prior first dose study drug . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) &lt; 2 . Main 1 . Is currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose treatment . 2 . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 agent patient previously participate MK3475 clinical trial . 3 . Has receive livevirus vaccination within 30 day plan treatment start . Note : Seasonal flu vaccine contain live virus permit . 4 . Prior allogeneic stem cell transplantation ( SCT ) . 5 . Major surgery within 4 week prior first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>